Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.

F, Pagès; T, André; J, Taieb; D, Vernerey; J, Henriques; C, Borg; F, Marliot; Jannet R, Ben; C, Louvet; L, Mineur; J, Bennouna; J, Desrame; R, Faroux; A, Kirilovsky; A, Duval; P, Laurent-Puig; M, Svrcek; F, Hermitte; A, Catteau; J, Galon; JF, Emile

doi:10.1016/j.annonc.2020.03.310

Public

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.

Shared by NobleBlocks on Apr 12, 2020 • 12:00 AM UTC

Authors:

Pagès F

André T

Taieb J

Abstract

Background The Immunoscore (IS), which prognostically classifies stage I-III colon cancer (CC) patients, was evaluated in the International Duration Evaluation of Adjuvant Therapy (IDEA) France cohort study investigating 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy in stage III CC pa...

Subject

Prognostic

Biomarker

Chemotherapy

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!